Press Releases Santen Pharmaceutical Co., Ltd.

Equities

4536

JP3336000009

Delayed Japan Exchange Other stock markets 12:12:54 2024-06-11 am EDT			5-day change	1st Jan Change
1,632 ^JPY	+0.77%		-0.40%	+16.19%

May. 10	Santen Pharmaceutical Intends to Buy Back and Cancel up to 38 Billion Yen Worth of Shares	MT
May. 09	Santen Pharmaceutical Co., Ltd. announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Santen Pharmaceutical : Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis, goes on sale in Japan	May. 21	PU
Santen Pharmaceutical : Announces Share Buyback	May. 09	PU
Santen Pharmaceutical : Reports Fiscal 2023 Consolidated Performance	May. 09	PU
Santen Pharmaceutical : Notice of Board of Director and Corporate Auditor Nominations	May. 09	PU
Santen Pharmaceutical : and Mitsubishi Tanabe Pharma announce the conclusion of a contract for the joint sales promotion in Japan of Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis	May. 06	PU
Santen Pharmaceutical : and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL	Apr. 17	PU
Santen Pharmaceutical : Positioned for Further Growth in China Following Completion of Vision Park	Apr. 16	PU
Santen Pharmaceutical : obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis	Mar. 26	PU
Santen Pharmaceutical : Announces Change of Representative Director of the Board	Mar. 25	PU
Santen Pharmaceutical : Announces Cancellation of Treasury Shares	Mar. 25	PU
Santen Pharmaceutical : Announces Completion of Share Buyback	Mar. 25	PU
Santen Pharmaceutical : Announces Status of Share Buyback	Mar. 01	PU
Santen Pharmaceutical : Receives European Commission Approval for Catiolanze® (cationic emulsion of latanoprost 50μg/mL) for Lowering of Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension	Nov. 16	PU
Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America	23-07-19	AQ
Harrow Acquires Santen's Branded Ophthalmic Portfolio	23-07-19	AQ
Santen Pharmaceutical Co., Ltd. - Ophthalmic VEGF inhibitor Eylea Solution for Intravitreal Injection 40 mg/mL obtains approval for ROP as sixth indication	22-09-27	AQ
Santen and UBE Received FDA Approval for OMLONTI 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension	22-09-27	AQ
Santen Pharmaceutical : Announces Status of Share Buyback	22-08-01	PU
Santen Pharmaceutical : Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program	22-07-22	PU
Santen Pharmaceutical : Announces Status of Share Buyback	22-07-01	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Santen Pharmaceutical Co., Ltd.

Equities

4536

JP3336000009

Press Releases

Filters